The Pacific Ovarian Cancer Research Consortium (POCRC) is a community-based, multidisciplinary, translational research program that involves clinicians, laboratory scientists and public health scientists from six research and medical institutions on the Pacific Coast. The community-based approach allows the pooling of clinical resources to facilitate population-based studies despite the low incidence of ovarian cancer. The themes of the program are biomarkers for risk and early detection of disease, molecular targets for prognosis and therapy, and antigens for immunotherapy. We hypothesize that through early detection we can improve outcomes significantly because currently available treatments are more effective in disease confined to the ovary;new, less toxic immunotherapeutic approaches are expected to be particularly effective in early-stage disease. The POCRC will conduct 5 translational research projects including a screening trial in high-risk women using serum markers validated in preclinical samples, a novel imaging trial using targeted microbubbles to improve ultrasound performance, validation of a microRNA plasma signature for respectability, exploration of restoration of wild-type BRCA1 function in the development of resistance to cicplatin, and a Phase 1 trial of an anti-lGFBP2 vaccine. Each project addresses at least one of the translational areas outlined in the SPORE guidelines and together the program addresses 5 of the 6 translational pathways defined by the TRWG, All projects build on work performed during the current and previous funding periods. A Developmental Research Program and a Career Development Program are also included as part of our Renewal. Projects are supported by a Leadership and Administration Core, a Clinical Specimen Management and Characterization Core, a Participant Recruitment, Enrollment and Characterization Core, and a Biostatistics and Data Management Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083636-14
Application #
8322546
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Arnold, Julia T
Project Start
1999-09-30
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
14
Fiscal Year
2012
Total Cost
$2,296,158
Indirect Cost
$739,014
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Stephan, Sirkka B; Taber, Alexandria M; Jileaeva, Ilona et al. (2015) Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol 33:97-101
Karlan, Beth Y; Thorpe, Jason; Watabayashi, Kate et al. (2014) Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. Cancer Epidemiol Biomarkers Prev 23:1383-93
Cecil, Denise L; Holt, Gregory E; Park, Kyong Hwa et al. (2014) Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. Cancer Res 74:2710-8
Palanca-Wessels, Maria Corinna; Press, Oliver W (2014) Advances in the treatment of hematologic malignancies using immunoconjugates. Blood 123:2293-301
Miller, Chris P; Thorpe, Jason D; Kortum, Amanda N et al. (2014) JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors. Cancer Immunol Res 2:301-6
Topp, Monique D; Hartley, Lynne; Cook, Michele et al. (2014) Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol 8:656-68
Pennington, Kathryn P; Walsh, Tom; Harrell, Maria I et al. (2014) Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20:764-75
Cheon, Dong-Joo; Orsulic, Sandra (2014) Ten-gene biomarker panel: a new hope for ovarian cancer? Biomark Med 8:523-6
Duggan, Catherine; Wang, Ching-Yun; Xiao, Liren et al. (2014) Aspirin and serum estrogens in postmenopausal women: a randomized controlled clinical trial. Cancer Prev Res (Phila) 7:906-12
Emori, Megan M; Drapkin, Ronny (2014) The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis. Reprod Biol Endocrinol 12:60

Showing the most recent 10 out of 129 publications